Triad Isotopes, Inc. Sustainability Profile
Triad Isotopes, Inc., a leading provider in the nuclear medicine industry, is headquartered in the United States and operates across several major regions. Founded in 2007, the company has established itself as a key player in the production and distribution of radiopharmaceuticals, catering to hospitals and clinics nationwide. Specialising in the development of innovative diagnostic and therapeutic isotopes, Triad Isotopes offers unique solutions that enhance patient care and improve clinical outcomes. Their commitment to quality and safety has earned them a strong market position, recognised for their reliable supply chain and exceptional customer service. With a focus on advancing nuclear medicine, Triad Isotopes continues to achieve notable milestones, contributing significantly to the healthcare landscape and the ongoing evolution of medical imaging and treatment.
DitchCarbon Score
How does Triad Isotopes, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Triad Isotopes, Inc.'s score of 50 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Triad Isotopes, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported emissions figures. The company is a current subsidiary of Jubilant Pharma Limited, which may influence its climate commitments and emissions reporting. While there are no documented reduction targets or specific climate pledges from Triad Isotopes, Inc., it is important to note that emissions data and performance metrics may be inherited from its parent company, Jubilant Pharmova Limited, at a cascade level of 2. This means that any climate initiatives or emissions reductions undertaken by Jubilant Pharmova Limited could potentially reflect on Triad Isotopes, Inc. As of now, Triad Isotopes, Inc. has not publicly committed to any specific science-based targets or initiatives related to carbon emissions reduction. The company’s climate strategy and performance may evolve as it aligns with the broader sustainability goals of its parent organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2015 | 2016 | 2017 | 2019 | 2020 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 894,456,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 107,906,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 12,057,000 | - | - | - | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Triad Isotopes, Inc.'s Industry?
How Carbon Intensive is Triad Isotopes, Inc.'s Location?
Triad Isotopes, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Triad Isotopes, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
